Advanced search
Publication Cover
Expert Review of Hematology Volume 8, 2015 - Issue 4
Submit an article Journal homepage
1,287
Views
21
CrossRef citations to date
0
Altmetric
Review

Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events

Benedito A CarneiroNorthwestern Medicine Developmental Therapeutics Institute, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA;Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USACorrespondence[email protected]
,
Jason B KaplanNorthwestern Medicine Developmental Therapeutics Institute, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA;Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
&
Francis J GilesNorthwestern Medicine Developmental Therapeutics Institute, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA;Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Pages 457-479 | Published online: 04 May 2015

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Seniz Ongoren, Ahmet Emre Eskazan, Veysel Suzan, Sercan Savci, Isil Erdogan Ozunal, Selin Berk, Fevzi Fırat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Yucel Erbilgin, Sibel Aylin Iseri, Muhlis Cem Ar, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek & Teoman Soysal. (2018) Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology 23:4, pages 212-220.
Read now
Ingolf Cascorbi & Anneke Nina Werk. (2017) Advances and challenges in hereditary cancer pharmacogenetics. Expert Opinion on Drug Metabolism & Toxicology 13:1, pages 73-82.
Read now
Dilek Keskin, Sevil Sadri & Ahmet Emre Eskazan. (2016) Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Design, Development and Therapy 10, pages 3355-3361.
Read now
Onur Kirkizlar & Ahmet Emre Eskazan. (2016) Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Review of Quality of Life in Cancer Care 1:5, pages 353-359.
Read now

Articles from other publishers (17)

Hiroyuki Arai, Shinya Yamamoto, Takeshi Matsubara, Takafumi Miyake, Akira Tochio, Akiko Mii, Akira Shimizu, Sachiko Minamiguchi, Eri Muso & Motoko Yanagita. (2023) Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib: A Case Report. Internal Medicine.
Crossref
Lauren A. Baldassarre, Sarju Ganatra, Juan Lopez-Mattei, Eric H. Yang, Vlad G. Zaha, Timothy C. Wong, Chadi Ayoub, Jeanne M. DeCara, Susan Dent, Anita Deswal, Arjun K. Ghosh, Mariana Henry, Abhishek Khemka, Monika Leja, Lawrence Rudski, Hector R. Villarraga, Jennifer E. Liu, Ana Barac & Marielle Scherrer-Crosbie. (2022) Advances in Multimodality Imaging in Cardio-Oncology. Journal of the American College of Cardiology 80:16, pages 1560-1578.
Crossref
Cong-Yu Wang, Min Sun, Zhen Fan & Jian-Zhong Du. (2022) Intestine Enzyme-responsive Polysaccharide-based Hydrogel to Open Epithelial Tight Junctions for Oral Delivery of Imatinib against Colon Cancer. Chinese Journal of Polymer Science 40:10, pages 1154-1164.
Crossref
Mathilde Strumia, Marie-Loup Perrin, Emilie Patras de Compaigno, Cécile Conte, Francois Montastruc, Maryse Lapeyre-Mestre, Vincent Sibaud & Fabien Despas. (2022) Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®. Therapies 77:2, pages 219-227.
Crossref
Kennedy D. MahdaviSheldon E. JordanHannah R. BarrowsMaša PravdicBarshen HabelhahNatalie E. EvansRobin B. BladesJessica J. IovineSergio A. BecerraRachel A. SteinerMarisa ChangSantosh KesariAlexander BystritskyEd O'ConnorHyman GrossF. Scott PerelesMike WhitneyTaylor Kuhn. (2021) Treatment of Dementia With Bosutinib. Neurology Clinical Practice 11:3.
Crossref
Fernanda Salles Seguro, Carolina Maria Pinto Domingues Carvalho Silva, Carla Maria Boquimpani de Moura, Monika Conchon, Laura Fogliatto, Vaneuza Araujo Moreira Funke, André Abdo, Ariane Vieira Scarlatelli Macedo, Marilia Harumi Higushi dos Santos & José Francisco Kerr Saraiva. (2021) Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring. Hematology, Transfusion and Cell Therapy 43:2, pages 191-200.
Crossref
Li Zhang, Li Meng, Bingcheng Liu, Yanli Zhang, Huanling Zhu, Jiuwei Cui, Aining Sun, Yu Hu, Jie Jin, Hao Jiang, Xi Zhang, Yan Li, Li Liu, Wanggang Zhang, Xiaoli Liu, Jian Gu, Jianhui Qiao, Guifang Ouyang, Xin Liu, Jianmin Luo, Ming Jiang, Xiaobao Xie, Jianyong Li, Chunting Zhao, Mei Zhang, Tonghua Yang & Jianxiang Wang. (2021) Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study. Clinical Cancer Research 27:1, pages 70-77.
Crossref
Yoshinobu Seki, Ouki Nagano, Ryo Koda, Shinichi Morita & Go Hasegawa. (2020) Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy. International Journal of Hematology 112:4, pages 584-591.
Crossref
Mariana M. Fachi, Fernanda S. Tonin, Leticia P. Leonart, Inajara Rotta, Fernando Fernandez‐Llimos & Roberto Pontarolo. (2019) Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta‐analysis. British Journal of Clinical Pharmacology 85:10, pages 2280-2291.
Crossref
Yan Li, Baohui Yang & Xingwang Zhang. (2019) Oral delivery of imatinib through galactosylated polymeric nanoparticles to explore the contribution of a saccharide ligand to absorption. International Journal of Pharmaceutics 568, pages 118508.
Crossref
Chikara HIRASE & Itaru MATSUMURA. (2018) Thromboembolism in TKI therapyチロシンキナーゼ阻害薬（TKI）治療と血栓塞栓症. Japanese Journal of Thrombosis and Hemostasis 29:5, pages 473-486.
Crossref
Lucy C. FoxKatherine D. CumminsBen CostelloDavid YeungRebecca ClearyCecily ForsythMaciek TatarczuchKate BurburyOlga MotornaJake ShorttShaun FlemingAndrew McQuillanAnthony SchwarerRosemary HarrupAmy HolmesSumita RatnasingamKah-Lok ChanWei-Hsun Hsu, Asma Ashraf, Faye PuttAndrew Grigg. (2017) The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Advances 1:13, pages 802-811.
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 415 434 .
Valentín García-Gutiérrez, Antonio Jiménez-Velasco, M. Teresa Gómez-Casares, Fermín Sánchez-Guijo, Jose Luis López-Sendón & Juan Luis Steegmann Olmedillas. (2016) Gestión cardiovascular de los pacientes con leucemia mieloide crónica desde una perspectiva multidisciplinar, y propuesta de protocolo de actuación por reunión de consenso. Medicina Clínica 146:12, pages 561.e1-561.e8.
Crossref
Valentín García-Gutiérrez, Antonio Jiménez-Velasco, M. Teresa Gómez-Casares, Fermín Sánchez-Guijo, Jose Luis López-Sendón & Juan Luis Steegmann Olmedillas. (2016) Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting. Medicina Clínica (English Edition) 146:12, pages 561.e1-561.e8.
Crossref
Zhishan Cui, Xi Li, Lulu Li, Bin Zhang, Chunmei Gao, Yuzong Chen, Chunyan Tan, Hongxia Liu, Weiyi Xie, Ti Yang & Yuyang Jiang. (2016) Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment. Bioorganic & Medicinal Chemistry 24:2, pages 261-269.
Crossref
Luc Bressollette, Philippe Quéhé & Simon Gestin. 2016. Maladies Artérielles. Maladies Artérielles 495 497 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.